Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,171 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Obstructive Lung Disease Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT03162055
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease COPD
Interventions
Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 95 Years
Enrollment
1,119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Tempe, Arizona • Escondido, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 13, 2026, 9:58 AM EDT
Withdrawn Not applicable Interventional

The Impact of Interprofessional Training to Improve the Uptake of Noninvasive Ventilation in Patients Hospitalized With Severe COPD Exacerbation

NCT04206735
View directory record Official record
Conditions
Copd
Interventions
Interprofessional Education (IPE), Usual care
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
23 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 1 Interventional

Comparative Effects of Fish Oil Supplementation and a Montelukast on EIB and Airway Inflammation in Asthma

NCT00676468
View directory record Official record
Conditions
Asthma
Interventions
Active Montelukast + Fish Oil Placebo, Active Fish Oil + Montelukast Placebo, Active Montelukast + Active Fish Oil
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 13, 2026, 9:58 AM EDT
Recruiting Phase 2 Interventional

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT06660355
View directory record Official record
Conditions
Chronic Graft-versus-host Disease (cGVHD)
Interventions
Ruxolitinib, Prednisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Miami, Florida • Tampa, Florida • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Not applicable Interventional

Asthma and Indoor-air: Reducing Exposures

NCT01869543
View directory record Official record
Conditions
Asthma
Interventions
Stand Alone Air Cleaner, HVAC Modification
Other
Lead sponsor
University of California, Davis
Other
Eligibility
6 Years to 12 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

NCT04400318
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 13, 2026, 9:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

NCT04722835
View directory record Official record
Conditions
Copd, Smoking, Tobacco Use
Interventions
Bronchoscopy with Bronchoalveolar Lavage (BAL)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 13, 2026, 9:58 AM EDT
Terminated No phase listed Observational

Efficacy of High Flow Therapy in COPD At Home

NCT02230020
View directory record Official record
Conditions
COPD
Interventions
Nasal High Flow
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

NCT03265145
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy), LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
90
States / cities
Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 13, 2026, 9:58 AM EDT
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

NCT01174732
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol inhalation powder, Placebo, albuterol inhalation aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
San Jose, California • Centennial, Colorado • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

NCT02969408
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
44
States / cities
Litchfield Park, Arizona • Bakersfield, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 13, 2026, 9:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children

NCT00454415
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
9 Years to 14 Years
Enrollment
16,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

NCT02031640
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate, Placebo, Albuterol/salbutamol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
94
States / cities
Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

NCT00927758
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 13, 2026, 9:58 AM EDT
Not listed No phase listed Observational

Intravenous Terbutaline in Severe Status Asthmaticus

NCT00750568
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
2 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Louisville, Kentucky • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Not applicable Interventional Results available

Trial of Montelukast for Treatment of Acute Bronchiolitis

NCT00863317
View directory record Official record
Conditions
Bronchiolitis
Interventions
montelukast sodium, sucrose
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Months to 12 Months
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01879410
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 13, 2026, 9:58 AM EDT
Active, not recruiting Phase 2 Interventional

Preventing Asthma in High Risk Kids

NCT02570984
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
24 Months to 47 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
13
States / cities
Phoenix, Arizona • San Diego, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 13, 2026, 9:58 AM EDT
Completed Not applicable Interventional Results available

Investigation of the Role of Pictorial Asthma Action Plans to Promote Self-management in Rural Youth With Asthma

NCT03187119
View directory record Official record
Conditions
Asthma
Interventions
Pictorial Asthma Action Plan, Written Asthma Action Plan
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
8 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 13, 2026, 9:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Allergy and Immunology Natural History Study

NCT05584488
View directory record Official record
Conditions
Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 13, 2026, 9:58 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Assess the Suitability of the HealthBeacon Injection Care Management System (ICMS) as a Remote Therapeutic Monitoring (RTM) Device

NCT05592769
View directory record Official record
Conditions
Respiratory Disease
Interventions
HealthBeacon Injection Care Management System (ICMS)
Device
Lead sponsor
HealthBeacon Plc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 13, 2026, 9:58 AM EDT